TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine

The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted provisional determination to Vaxine Pty Ltd in relation to its COVID-19 vaccine: Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed).

This recombinant (genetically engineered) protein vaccine will be considered for active immunisation to prevent COVID-19 caused by SARS-CoV-2. If approved, a complete course of the Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 vaccine is potentially two doses given as an intramuscular injection 3 weeks apart.

https://www.tga.gov.au/tga-grants-provisional-determination-vaxine-pty-ltd-its-covid-19-recombinant-protein-vaccine